Bristol-Myers Squibb Co. acquired exclusive, worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) for HIV, from Oncolys BioPharma Inc., of Tokyo, a privately held company.